Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRESY vs HHS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRESY Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

CRESY Overall Winner 6-Pillar Tally: CRESY 4 – 1 HHS (1 Tie) Matrix Metrics: CRESY 6 – 4 HHS

As of Nov 16, 2026, Cresud SA (CRESY) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRESY carries a Unified Composite Score of 54.6/100 (HOLD) at $9.17 (56.6x Forward P/E, 19.3% operating margin), whereas HHS carries 61.8/100 (BUY) at $3.85 (14.3x Forward P/E, -3.2% operating margin).

  • Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. CRESY 54.6/100 HOLD), CRESY captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -3.2% operating margin) and revenue trajectory (+20.4% vs. -1.7% YoY).
  • Technical & Structure Timing Caution: CRESY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.6); meanwhile HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRESY vs HHS
CRESY NASDAQ Head-to-Head Winner
Cresud SA
Real Estate
$9.17
-5.85% 1D
Market Cap $690.8M
TTM Revenue $1.15B
Forward P/E 56.6x
Beta / 30D Vol 0.82β · 59% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 75.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 37
RSI-14: 36.6 · SMA20: $10.07 · SMA50: $11.20
HHS US Equity
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.85
-3.99% 1D
Market Cap $29.9M
TTM Revenue $155M
Forward P/E 14.3x
Beta / 30D Vol 0.49β · 46% Vol
Unified Composite Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.2 · SMA20: $3.95 · SMA50: $4.26

6-Pillar Scorecard Institutional Category Breakdown (CRESY 4 – 1 HHS)

Columns: Metric · CRESY · HHS
1. Valuation Multiples HHS
Forward P/E 56.6x 14.3x
Trailing P/E 6.3x 14.3x
PEG Ratio N/M 1.19x
EV / Revenue 0.6x 0.3x
2. Growth & Scale CRESY
Revenue Growth (YoY) +20.4% -1.7%
Earnings Growth (YoY) -93.6% -90.3%
TTM Revenue (USD) $1.15B $155M
Market Cap $690.8M $29.9M
3. Profitability & Quality CRESY
Gross Margin 42.1% 16.1%
Operating Margin 19.3% -3.2%
Net Profit Margin 9.6% -3.7%
Return on Equity (ROE) 8.6% -30.4%
4. Balance Sheet & Cash Flow CRESY
Cash Generation (TTM) $236M EBITDA -$4.5M
Cash Flow Margin 20.6% EBITDA Mgn -2.9%
Net Cash / Leverage $14.10 Book/Sh · 8.6% ROE $17M Net Debt (1.10x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 74.0% (100th %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CRESY
OpEx & R&D Intensity 22.8% of Rev ($262M) 19.3% of Rev ($30M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Conglomerates Operator Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRESY (6) vs HHS (4)
Institutional Metric CRESY HHS Criterion Row Edge
Market Capitalization
Scale
$690.8M $29.9M Larger Scale CRESY
Trailing P/E Ratio
Valuation
6.3x 14.3x Lower Multiple CRESY
Forward P/E Ratio
Valuation
56.6x 14.3x Lower Multiple HHS
Revenue Growth (YoY)
Growth
+20.4% -1.7% Higher Growth CRESY
Operating Margin (TTM)
Profitability
19.3% -3.2% Higher Margin CRESY
Net Profit Margin
Profitability
9.6% -3.7% Higher Margin CRESY
Return on Equity (ROE)
Capital Efficiency
8.6% -30.4% Higher ROE CRESY
52-Week Range Position
Momentum
8% ($9–$14) 69% ($2–$5) Stronger Trend HHS
Beta / 30D Volatility
Risk Regime
0.82β · 59% Vol 0.49β · 46% Vol Lower Realized Risk HHS
Unified Institutional Score
Composite Signal
54.6 / 100 (HOLD) 61.8 / 100 (BUY) Higher Composite HHS
Trailing 12M Revenue (USD)
Operating Scale
$1.15B $155M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.1% 16.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev 1.19x PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$236M EBITDA ($14.10 Book/Sh · 8.6% ROE) -$4.5M ($17M Net Debt (1.10x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HHS +10.14 pp
CRESY: -20.4% · HHS: -10.26%
3M Horizon HHS +8.06 pp
CRESY: -11.57% · HHS: -3.51%
6M Horizon HHS +54.28 pp
CRESY: -17.76% · HHS: +36.52%
1Y Horizon HHS +55.35 pp
CRESY: -20.26% · HHS: +35.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRESY vs HHS. Trailing 12-month operating profitability (CRESY 19.3% vs HHS -3.2%) and valuation multiples (CRESY 56.6x vs HHS 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.

CRESY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.15B
Gross Margin42.1%
Op. Margin19.3%
ROE / Fwd P/E8.6% · 56.6x
HHS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$155M
Gross Margin16.1%
Op. Margin-3.2%
ROE / Fwd P/E-30.4% · 14.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRESY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 74.0%
IV Percentile 100th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CRESY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HHS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HHS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRESY Moat Profile Scale & Operating Efficiency Moat
Conglomerates Operator
Competes within the Conglomerates value chain with $690.8M market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment 22.8% of Rev ($262M)
90D Engineering Disclosures 0 Published
HHS Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $29.9M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($30M)
90D Engineering Disclosures 0 Published

Investor FAQ CRESY vs HHS Key Questions & Quantitative Answers

As of Nov 16, 2026, Cresud SA (CRESY) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRESY carries a Unified Composite Score of 54.6/100 (HOLD) at $9.17 (56.6x Forward P/E, 19.3% operating margin), whereas HHS carries 61.8/100 (BUY) at $3.85 (14.3x Forward P/E, -3.2% operating margin). Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. CRESY 54.6/100 HOLD), CRESY captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -3.2% operating margin) and revenue trajectory (+20.4% vs. -1.7% YoY). Technical & Structure Timing Caution: CRESY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.6); meanwhile HHS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRESY leads the Growth & Scale pillar: CRESY posts +20.4% YoY revenue growth and -93.6% YoY earnings growth on $1.15B TTM revenue (42.1% gross margin, 19.3% operating margin), compared with HHS at -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin). On trailing 12-month operating scale, CRESY generates $1.15B in USD-normalized revenue versus $155M for HHS. In operating R&D and SG&A reinvestment, CRESY deploys 22.8% of Rev ($262M) (0 90-day corporate R&D disclosures) versus 19.3% of Rev ($30M) (0 disclosures) for HHS.

HHS screens cheaper on headline valuation multiples. CRESY trades at 56.6x Forward P/E, 6.3x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (20.6% EBITDA margin), whereas HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRESY (8.6% ROE) versus HHS (-30.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CRESY carries 74.0% implied volatility (100th %ile, Extreme (>80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.82β · 59% Vol realized risk). By comparison, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.